48 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Substituted oxopyridine derivatives and use thereof as factor XIa/plasma
Bayer Pharma Aktiengesellschaft
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds
Parion Sciences
Substituted tetrahydrocarbazole and carbazole carboxamide compounds
Bristol-Myers Squibb
1,4-benzodiazepone-2,5-diones and related compounds with therapeutic properties
The Regents of The University of Michigan
Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
Merck Sharp & Dohme
Compounds, compositions and methods useful for cholesterol mobilization
Cerenis Therapeutics Holding
Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
Reset Therapeutics
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
Schering-Plough Research Institute
Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.
Johnson & Johnson Pharmaceutical
Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1.
University of Southampton
Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
Abbott Laboratories
Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.
Bristol-Myers Squibb
Beta-substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core.
Merck Frosst Centre For Therapeutic Research
A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
Merck Frosst Centre For Therapeutic Research
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.
Merck Frosst Centre For Therapeutic Research
Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Merck Frosst Centre For Therapeutic Research
(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.
Astellas Pharma
Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.
Ligand Pharmaceuticals
N(4)-Phenyl modifications of N(2)-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.
Nih
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.
Nih
Pyrazole inhibitors of HMG-CoA reductase: An attempt to dramatically reduce synthetic complexity through minimal analog re-design.
Pfizer
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Pfizer
Thermodynamic characterization of the binding of nucleotides to glycyl-tRNA synthetase.
Medical College of Ohio
The 1.15A crystal structure of the Staphylococcus aureus methionyl-aminopeptidase and complexes with triazole based inhibitors.
Morphochem
Design and Synthesis of HIV-1 Protease Inhibitors Incorporating Oxazolidinones as P2/P2' Ligands in Pseudosymmetric Dipeptide Isosteres.
University of Massachusetts Medical School